"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Descriptor ID |
D002292
|
MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Adenocarcinoma Of Kidney
- Adenocarcinoma Of Kidneys
- Kidney, Adenocarcinoma Of
- Kidneys, Adenocarcinoma Of
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal
- Adenocarcinomas, Renal
- Renal Adenocarcinoma
- Renal Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
- Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Grawitz Tumor
- Tumor, Grawitz
- Clear Cell Renal Carcinoma
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Hypernephroma
- Hypernephromas
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 0 | 1 |
1994 | 2 | 0 | 2 |
1995 | 2 | 0 | 2 |
1996 | 1 | 2 | 3 |
1997 | 3 | 0 | 3 |
1998 | 5 | 0 | 5 |
1999 | 2 | 0 | 2 |
2000 | 8 | 0 | 8 |
2001 | 3 | 3 | 6 |
2002 | 8 | 0 | 8 |
2003 | 5 | 1 | 6 |
2004 | 13 | 1 | 14 |
2005 | 10 | 3 | 13 |
2006 | 17 | 2 | 19 |
2007 | 11 | 1 | 12 |
2008 | 17 | 0 | 17 |
2009 | 12 | 0 | 12 |
2010 | 12 | 2 | 14 |
2011 | 6 | 2 | 8 |
2012 | 4 | 1 | 5 |
2013 | 13 | 2 | 15 |
2014 | 14 | 2 | 16 |
2015 | 11 | 1 | 12 |
2016 | 18 | 0 | 18 |
2017 | 8 | 1 | 9 |
2018 | 11 | 2 | 13 |
2019 | 11 | 0 | 11 |
2020 | 10 | 2 | 12 |
2021 | 12 | 3 | 15 |
2022 | 10 | 0 | 10 |
2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 Sep 07; 28(9):e748-e755.
-
Cystic MED15::TFE3 translocation renal cell carcinoma: histologic mimicker of multilocular cystic renal neoplasm of low malignant potential with review of the literature. Hum Pathol. 2023 06; 136:25-33.
-
Top 10 Clear Cell Head and Neck Lesions to Contemplate. Head Neck Pathol. 2023 Mar; 17(1):33-52.
-
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol. 2023 04; 134:124-133.
-
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci Adv. 2022 12 16; 8(50):eabp8293.
-
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. Gynecol Oncol. 2023 02; 169:164-171.
-
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
-
Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma. Histopathology. 2022 Nov; 81(5):577-586.
-
The emerging role of NF2 alterations in new and established subtypes of renal cell carcinoma. Hum Pathol. 2023 03; 133:87-91.
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.